Silvia Buonamici

10.7k total citations
55 papers, 3.0k citations indexed

About

Silvia Buonamici is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Silvia Buonamici has authored 55 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 28 papers in Hematology and 12 papers in Genetics. Recurrent topics in Silvia Buonamici's work include Acute Myeloid Leukemia Research (24 papers), RNA Research and Splicing (13 papers) and Ubiquitin and proteasome pathways (10 papers). Silvia Buonamici is often cited by papers focused on Acute Myeloid Leukemia Research (24 papers), RNA Research and Splicing (13 papers) and Ubiquitin and proteasome pathways (10 papers). Silvia Buonamici collaborates with scholars based in United States, Italy and China. Silvia Buonamici's co-authors include Iannis Aifantis, Elizabeth A. Raetz, Benjamin J. Thompson, Tomas Vilimas, Teresa Palomero, Adolfo A. Ferrando, Giuseppe Basso, Maria Luisa Sulis, Giuseppina Nucifora and Anant A. Agrawal and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Silvia Buonamici

54 papers receiving 3.0k citations

Peers

Countries citing papers authored by Silvia Buonamici

Since Specialization

Citations

This map shows the geographic impact of Silvia Buonamici's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvia Buonamici with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvia Buonamici more than expected).

Fields of papers citing papers by Silvia Buonamici

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvia Buonamici. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvia Buonamici. The network helps show where Silvia Buonamici may publish in the future.

Co-authorship network of co-authors of Silvia Buonamici

This figure shows the co-authorship network connecting the top 25 collaborators of Silvia Buonamici. A scholar is included among the top collaborators of Silvia Buonamici based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvia Buonamici. Silvia Buonamici is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML 2024 ·Science Translational Medicine ·Emily C. Wheeler, Benjamín Martín, (unknown), (unknown), (unknown), (unknown), (unknown), Melanie Donahue, (unknown), Omar Abdel‐Wahab, Justin Taylor, Michael Seiler, Silvia Buonamici, Yana Pikman, Jacqueline S. Garcia, Roger Belizaire, Karen Adelman, Zuzana Tóthová	17
2	REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML 2024 ·Blood ·(unknown), Michael Thomas, (unknown), (unknown), Alexander E. Ivliev, Adam Štefek, Michael D. Cameron, Sudeep Prajapati, Michael Seiler, Dominic J. Reynolds, Silvia Buonamici, Charles Kung	1
3	Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma 2018 ·EBioMedicine ·Rocco Sciarrillo, Anna Wojtuszkiewicz, Btissame El Hassouni, Niccola Funel, Paolo Gandellini, Tonny Lagerweij, Silvia Buonamici, (unknown), (unknown), Nadia Zaffaroni, Marcello Deraco, Shigeki Kusamura, Tom Würdinger, Godefridus J. Peters, Carla F.M. Molthoff, Gerrit Jansen, Gertjan J.L. Kaspers, Jacqueline Cloos, Elisa Giovannetti	47
4	The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action 2018 ·Genes & Development ·Lorenzo I. Finci, Xiaofeng Zhang, Xiuliang Huang, Qiang Zhou, Jennifer Tsai, Teng Teng, Anant A. Agrawal, Betty Chan, Sean Irwin, Craig Karr, Andrew S. Cook, Ping Zhu, Dominic J. Reynolds, Peter G. Smith, Peter Fekkes, Silvia Buonamici, Nicholas Larsen	91
5	Structural Basis of Splicing Modulation by Antitumor Macrolide Compounds 2018 ·Molecular Cell ·Constantin Cretu, Anant A. Agrawal, Andrew S. Cook, Cindy L. Will, Peter Fekkes, Peter G. Smith, Reinhard Lührmann, Nicholas Larsen, Silvia Buonamici, Vladimir Peña	125
6	Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival 2017 ·Molecular Cancer Therapeutics ·(unknown), Praveen Sridhar, Rory Kirchner, (unknown), Zach Herbert, Silvia Buonamici, Peter G. Smith, Judy Lieberman, Fabio Petrocca	36
7	Dynamic BH3 Profiling to Assess the Effects of Novel Agents on Anti-Apoptotic Protein Dependence of CLL Cells 2017 ·Blood ·Rebecca Valentin, Jing Deng, Elisa ten Hacken, (unknown), Silvia Buonamici, Donna Neuberg, Catherine J. Wu, Anthony Letai, Matthew S. Davids	1
8	Targeting splicing abnormalities in cancer 2017 ·Current Opinion in Genetics & Development ·Anant A. Agrawal, Lihua Yu, Peter G. Smith, Silvia Buonamici	61
9	Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation 2016 ·Cancer Cell ·Esther A. Obeng, (unknown), Michael Seiler, Michelle C. Chen, Dean R. Campagna, Paul J. Schmidt, Rebekka K. Schneider, Allegra M. Lord, Lili Wang, Rutendo Gambe, Marie McConkey, Abdullah Mahmood Ali, Azra Raza, Lihua Yu, Silvia Buonamici, Peter G. Smith, Ann Mullally, Catherine J. Wu, Mark D. Fleming, Benjamin L. Ebert	263
10	Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts 2016 ·Leukemia ·Annalisa Mupo, Magdalene J. Seiler, Vijitha Sathiaseelan, Alena Pance, (unknown), Anant A. Agrawal, Francesco Iorio, Ruben Bautista, (unknown), Konstantinos Tzelepis, Nicla Manes, Penny Wright, Elli Papaemmanuil, David G. Kent, (unknown), Silvia Buonamici, Niccolò Bolli, George S. Vassiliou	91
11	Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7 2008 ·The Journal of Experimental Medicine ·Benjamin J. Thompson, Vladimir Janković, Jie Gao, Silvia Buonamici, (unknown), (unknown), Jiří Zavadil, Stephen D. Nimer, Iannis Aifantis	145
12	Molecular pathogenesis of T-cell leukaemia and lymphoma 2008 ·Nature reviews. Immunology ·Iannis Aifantis, Elizabeth A. Raetz, Silvia Buonamici	291
13	Notches, NF-kBs and the Making of T Cell Leukemia 2007 ·Cell Cycle ·Iannis Aifantis, Tomas Vilimas, Silvia Buonamici	13
14	Targeted therapies in myelodysplastic syndromes: ASH 2003 review 2004 ·Seminars in Hematology ·Anna Candoni, Federico Silvestri, Silvia Buonamici, Donglan Li, (unknown), Naomi Galili, Giuseppina Nucifora, Azra Raza	10
15	Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression 2004 ·Leukemia Research ·Azra Raza, Silvia Buonamici, Laurie Lisak, (unknown), Donglan Li, (unknown), (unknown), (unknown), (unknown), (unknown), Muhammad Ali Mumtaz, Sefer Gezer, Parameswaran Venugopal, Poluru L. Reddy, Naomi Galili, Anna Candoni, Jack W. Singer, Giuseppina Nucifora	59
16	The role of EVI1 in normal and leukemic cells 2003 ·Blood Cells Molecules and Diseases ·Silvia Buonamici, Soumen Chakraborty, Vitalyi Senyuk, Giuseppina Nucifora	58
17	P/CAF and GCN5 acetylate the AML1/MDS1/EVI1 fusion oncoprotein 2003 ·Biochemical and Biophysical Research Communications ·Vitalyi Senyuk, Kislay K. Sinha, Soumen Chakraborty, Silvia Buonamici, Giuseppina Nucifora	9
18	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. 2001 ·PubMed ·Marilina Amabile, Barbara Giannini, Nicoletta Testoni, Vittorio Montefusco, Gianantonio Rosti, (unknown), Carolina Terragna, Silvia Buonamici, Emanuela Ottaviani, Simona Soverini, Mauro Fiacchini, Sebastián Bassi, Antonio De Vivo, Elena Trabacchi, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, S Tura, Giovanni Martinelli	36
19	Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study 2001 ·Leukemia ·Giuseppe Visani, Silvia Buonamici, Michele Malagola, Alessandro Isidori, Pier Paolo Piccaluga, Giovanni Martinelli, Emanuela Ottaviani, Tiziana Grafone, Michele Baccarani, S Tura	35
20	Real-time quantification of different types of BcrAbl transcript in chronic myeloid leukemia 2000 ·Blood ·Barbara Giannini, Vittorio Montefusco, (unknown), Nicoletta Testoni, (unknown), Carolina Terragna, Silvia Buonamici, Emanuela Ottaviani, Simona Bassi, (unknown), Michele Baccarani, Giuseppe Saglio, S Tura	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact